High incidence of peritoneal implants in recurrence of intra-abdominal cancer revealed by 18F-FDG PET/CT in patients with increased tumor markers and negative findings on conventional imaging

Nuclear Medicine Communications

Volumn 33, Issue 4, 2012, Pages 431-438

  Panagiotidis, Emmanouil ^a   Datseris, Ioannis Emmanouil ^a   Exarhos, Demetrios ^a   Skilakaki, Maria ^a   Skoura, Evangelia ^a   Bamias, Aristotelis ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ABDOMINAL CANCER; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DUODENUM CANCER; ENDOMETRIUM CANCER; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PANCREAS CANCER; PANCREAS CARCINOMA; PERITONEUM; PROSPECTIVE STUDY; RECURRENT CANCER; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SMALL INTESTINE CANCER; STOMACH CANCER; THYROID MEDULLARY CARCINOMA; UTERINE CERVIX CANCER;

ABDOMINAL NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PERITONEUM; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTHESES AND IMPLANTS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84858289531     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283506ae1     Document Type: Article

References (27)

1. Duffy MJ. Evidence for the clinical use of tumour markers. Ann Clin Biochem 2004; 41 (Pt 5):370-377. (Pubitemid 39279922)
2. Patt YZ, Podoloff DA, Curley S, Kasi L, Smith R, Bhadkamkar V, Charnsangavej C. Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. J Clin Oncol 1994; 12:489-495.
3. Bakalakos EA, Burak WE, Young DC, Martin EW. Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases? Am J Surg 1999; 177:2-6. (Pubitemid 29088988)
4. Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 2001; 38:225-262. (Pubitemid 32614076)
5. Hung GU, Shiau YC, Tsai SC, Chao TH, Ho YJ, Kao CH. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res 2001; 21 (2B):1375-1378.
6. Kurtz AB, Tsimikas JV, Tempany CM, Hamper UM, Arger PH, Bree RL, et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis: report of the Radiology Diagnostic Oncology Group. Radiology 1999; 212:19-27. (Pubitemid 29302506)
7. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003; 44:1200-1209. (Pubitemid 39655178)
8. Lynch TB. PET/CT in clinical practice. vi: London: Springer; p. 241.
9. Palomar A, Nanni C, Castellucci P, Ambrosini V, Montini G, Allegri V, et al. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. Mol Imag Biol 2011; 13:1-7.
10. Funicelli L, Travaini LL, Landoni F, Trifiro G, Bonello L, Bellomi M. Peritoneal carcinomatosis from ovarian cancer: the role of CT and [(1)F]FDG-PET/CT. Abdom Imag 2010; 35:701-707.
11. Israel O, Mor M, Guralnik L, Hermoni N, Gaitini D, Bar-Shalom R, et al. Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer? J Nucl Med 2004; 45:2045-2051. (Pubitemid 47611634)
12. Metser U, You J, McSweeney S, Freeman M, Hendler A. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR Am J Roentgenol 2010; 194:766-771.
13. Chen LB, Tong JL, Song HZ, Zhu H, Wang YC. (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol 2007; 13:5025-5029. (Pubitemid 47496838)
14. Bilici A, Ustaalioglu BB, Seker M, Canpolat N, Tekinsoy B, Salepci T, Gumus M. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management? Eur J Nucl Med Mol Imaging 2010; 37:1259-1269.
15. Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 2002; 85:53-58. (Pubitemid 34304010)
16. Jacquet P, Vidal-Jove J, Zhu B, Sugarbaker P. Peritoneal carcinomatosis from gastrointestinal malignancy: natural history and new prospects for management. Acta Chir Belg 1994; 94:191-197.
17. Tuxen MK, Strauss G, Lund B, Hansen M. The role of second-look laparotomy in the long-term survival in ovarian cancer. Ann Oncol 1997; 8:643-648. (Pubitemid 27372161)
18. Sijmons EA, Heintz AP. Second-look and second surgery: second chance or second best? Semin Surg Oncol 2000; 19:54-61. (Pubitemid 30439316)
19. Simojoki M, Santala M, Vuopala S, Kauppila A. The prognostic value of peritoneal cytology in ovarian cancer. Eur J Gynaecol Oncol 1999; 20 (5-6):357-360.
20. Shepherd NA, Baxter KJ, Love SB. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology 1997; 112:1096-1102. (Pubitemid 27157519)
21. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 2003; 44:1407-1412. (Pubitemid 39663352)
22. Dirisamer A, Schima W, Heinisch M, Weber M, Lehner HP, Haller J, Langsteger W. Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT. Eur J Radiol 2009; 69:536-541.
23. Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman E, Chi D, et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 2002; 223:495-499. (Pubitemid 34454332)
24. Cohade C, Osman M, Nakamoto Y, Marshall LT, Links JM, Fishman EK, Wahl RL. Initial experience with oral contrast in PET/CT: phantom and clinical studies. J Nucl Med 2003; 44:412-416. (Pubitemid 39586018)
25. Groves A, Kayani I, Dickson J, Townsend C, Croasdale I, Syed R, et al. Oral contrast medium in PET/CT: should you or shouldn't you? Eur J Nucl Med Mol Imag 2005; 32:1160-1166. (Pubitemid 41355942)
26. Blake M, Setty B, Cronin C, Kalra M, Holalkere N, Fischman A, et al. Evaluation of the effects of oral water and low-density barium sulphate suspension on bowel appearance on FDG-PET/CT. Eur Radiol 2010; 20:157-164.
27. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. Am J Roentgenol 2000; 174:1005-1008. (Pubitemid 30179992)